| 1 |
32390827 | Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients. | 2020 |
3 |
| 2 |
28744217 | The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation. | 2017 |
1 |
| 3 |
26894931 | Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. | 2016 Mar |
2 |
| 4 |
24768782 | Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy. | 2014 Jul 1 |
1 |
| 5 |
19501186 | In vitro micronucleus test in HepG2 transformants expressing a series of human cytochrome P450 isoforms with chemicals requiring metabolic activation. | 2009 Jun-Jul |
1 |
| 6 |
18496131 | Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. | 2008 Jun |
1 |
| 7 |
17580253 | Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. | 2007 Jul |
3 |
| 8 |
16183265 | Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. | 2006 Jan |
1 |
| 9 |
16475710 | CYP2C9 polymorphisms in human tumors. | 2006 Jan-Feb |
1 |
| 10 |
12684728 | Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. | 2003 Jun |
4 |
| 11 |
10991840 | Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. | 2000 Oct |
6 |
| 12 |
9157990 | Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. | 1997 May 15 |
1 |
| 13 |
9241661 | Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. | 1997 Jun |
7 |
| 14 |
9331082 | Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. | 1997 Oct 1 |
1 |